Galectin Therapeutics Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue - - - -
Cost of Revenue - - - -
Gross Profit - - - -
Operating Expenses
Research and Development 5,688 4,527 3,552 1,066
Sales, General and Admin. 6,416 5,372 6,857 3,817
Non-Recurring Items - - - -
Other - - - -
Operating Income (12,104) (9,899) (10,409) (4,883)
Income From Continuing Operations
Add'l Income/Expense Items 16 224 (506) (746)
Earnings Before Interest and Tax (12,088) (9,675) (10,915) (5,629)
Interest Expense - - - -
Earnings Before Tax (12,088) (9,675) (10,915) (5,629)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (12,088) (9,675) (10,915) (5,629)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (12,088) (9,675) (10,915) (5,629)
Preferred Stock and Other Adjustments (9,859) (1,206) (1,798) (3,080)
Net Income Applicable to Common Shareholders (21,947) (10,881) (12,713) (8,709)